Details for New Drug Application (NDA): 217190
✉ Email this page to a colleague
NDA 217190 describes HALOBETASOL PROPIONATE AND TAZAROTENE, which is a drug marketed by Taro and is included in one NDA. Additional details are available on the HALOBETASOL PROPIONATE AND TAZAROTENE profile page.
The generic ingredient in HALOBETASOL PROPIONATE AND TAZAROTENE is halobetasol propionate; tazarotene. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the halobetasol propionate; tazarotene profile page.
The generic ingredient in HALOBETASOL PROPIONATE AND TAZAROTENE is halobetasol propionate; tazarotene. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the halobetasol propionate; tazarotene profile page.
Summary for 217190
| Tradename: | HALOBETASOL PROPIONATE AND TAZAROTENE |
| Applicant: | Taro |
| Ingredient: | halobetasol propionate; tazarotene |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | LOTION;TOPICAL | Strength | 0.01%;0.045% | ||||
| Approval Date: | May 2, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
